An open‐label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0.005%, in patients with atopic dermatitis of the face and intertriginous areas

Background The treatment options for facial and intertriginous skin are limited because these sites are more susceptible to corticosteroid‐induced atrophy. The long‐term management of these corticosteroid‐sensitive sites requires the use of dosing regimens that are effective, but also safe.

[1]  A. Kligman,et al.  Corticosteroid‐induced atrophy and barrier impairment measured by non‐invasive methods in human skin , 2001, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging.

[2]  M. Lebwohl,et al.  Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas. , 2001, Journal of the American Academy of Dermatology.

[3]  W. Westerhof,et al.  Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. , 1999, Archives of dermatology.

[4]  J. Y. Lee,et al.  Corticosteroid skin atrophogenicity: assessment methods , 1998, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging.

[5]  P. Dykes,et al.  The kinetics of skin thinning induced by topical fluticasone propionate 0·05% cream in volunteer subjects , 1996, Clinical and experimental dermatology.

[6]  J. Delescluse,et al.  A comparison of the safety, tolerability, and efficacy of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of eczema. , 1996, Cutis.

[7]  M. Johnson.  Fluticasone propionate: safety profile. , 1996, Cutis.

[8]  M. Turpeinen,et al.  Pharmacokinetics of topical hydrocortisone at plasma level after applications once or twice daily in patients with widespread dermatitis , 1995, The British journal of dermatology.

[9]  S. Harding.  The human pharmacology of fluticasone propionate. , 1990, Respiratory medicine.

[10]  G. H. Phillipps.  Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. , 1990, Respiratory medicine.

[11]  R. Lavker,et al.  Corticosteroid atrophy in human skin. A study by light, scanning, and transmission electron microscopy. , 1983, The Journal of investigative dermatology.

[12]  N. Nielsen,et al.  Glaucoma induced by application of corticosteroids to the periorbital region. , 1978, Archives of dermatology.

[13]  R. Marshall,et al.  The effects on epidermal DNA synthesis of the butyrate esters of clobetasone and clobetasol, and the propionate ester of clobetasol , 1978, The British journal of dermatology.